Posted 11/21/18 on Technical.ly Baltimore The work at the University of Maryland aims to contribute to treatments that could lead to “HIV remission and possible eradication.” A team of Maryland researchers is leading an effort to develop a new HIV …
Submitted by Timna Wyckoff on November 20, 2018 – 10:15 Multi-specific anti-HIV antibodies that neutralize almost all circulating HIV-1 viruses will be optimized to target persistent infection IBBR researchers recently received $3.9 million from the National Institutes of Health (NIH) to develop …
Published 10/24/18 on Tech Transfer eNews Blog Preclinical stage drug developer GEn1E Lifesciences has entered into a license agreement with the University of Maryland-Baltimore (UMB) to commercialize a treatment for acute lung injury/acute respiratory distress syndrome (ALI/ARDS). Developed by UMB …
Published 10/22/18 in Maryland Today The University of Maryland SAFE Center for Human Trafficking Survivors has been awarded a $843,337 grant from the Maryland Governor’s Office of Crime Control and Prevention to maintain and expand its services. The SAFE Center, a …
Published on GeekWire, 10/22/18 Freelance science writer Berly McCoy uses a VR headset and controller to manipulate a virtual human brain at the Maryland Blended Reality Center. (GeekWire Photo / Alan Boyle) COLLEGE PARK, Md. — Can being in the middle …
Published 10/17/18 by GEn1E Lifesciences, Inc. Access to University of Maryland, Baltimore’s broadly applicable P38 Kinase inhibitor technology offers GEn1E the potential to enter the clinic with an acute lung injury/acute respiratory distress syndrome therapy PALO ALTO, Calif., Oct. 17, …
Published 10/8/18 in the Baltimore Business Journal University of Maryland, Baltimore-born startup Breethe Inc. is looking to raise about $5 million in new equity funding, according to a recent filing with the U.S. Securities and Exchange Commission. SEC documents …
Published 10/5/18 by University of Maryland CERSI The University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) has been renewed for funding under a cooperative agreement grant from the U.S. Food and Drug Administration (FDA). A collaborative …
Published 10/5/18 on UMB News The University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) has been renewed for funding under a cooperative agreement grant from the U.S. Food and Drug Administration (FDA). A collaborative partnership led by James Polli, …
Posted on 10/3/18 on PR Newswire New computational tool supports the engineering and development of cancer immunotherapies by predicting how T cell receptors recognize and bind to their targets ROCKVILLE, Md., Oct. 3, 2018 /PRNewswire/ — The Institute for Bioscience and Biotechnology Research (IBBR) has …